Liquidia Corp at Bank of America Global Healthcare Conference Transcript
My name is Jason Gerberry. I cover pharma and biotech at BFA. I'm pleased to be introducing Liquidia and joining us is Mike Casseta, CFO and COO, and Jason Adair, Chief Business Officer.
So, gentlemen, thanks for joining us. Liquidia has one of the more interesting commercial launches in biopharma since, I believe, June of last year and so we'll talk about that, your drug YUTREPIA for pulmonary arterial hypertension and PHILD. We'll talk a little bit about the pipeline as well.
So maybe we'll just start off and talk a little about YUTREPIA now, with three full quarters under your belt where you're at, what's exceeding expectations, and if you can talk a little bit about the opportunity on the come?
Questions & Answers
Yeah, thanks, Jason, and thanks for having us and hosting us here today.
Liquidia is a great place to be right now and as you said, we launched our product back in June of 2025, and we
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
